| 000 | 01723 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516221328.0 | ||
| 264 | 0 | _c20151026 | |
| 008 | 201510s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0099530 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAchhra, Amit C | |
| 245 | 0 | 0 |
_aMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial. _h[electronic resource] |
| 260 |
_bPloS one _c2014 |
||
| 300 |
_ae99530 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aAdenine _xadministration & dosage |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAlkynes |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzoxazines _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCyclohexanes _xadministration & dosage |
| 650 | 0 | 4 | _aCyclopropanes |
| 650 | 0 | 4 |
_aDideoxynucleosides _xadministration & dosage |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaraviroc |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganophosphonates _xadministration & dosage |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 | _aTenofovir |
| 650 | 0 | 4 |
_aTriazoles _xadministration & dosage |
| 700 | 1 | _aBoyd, Mark A | |
| 700 | 1 | _aLaw, Matthew G | |
| 700 | 1 | _aMatthews, Gail V | |
| 700 | 1 | _aKelleher, Anthony D | |
| 700 | 1 | _aCooper, David A | |
| 773 | 0 |
_tPloS one _gvol. 9 _gno. 6 _gp. e99530 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0099530 _zAvailable from publisher's website |
| 999 |
_c23956103 _d23956103 |
||